Cancer treatments have made significant progress in recent years, with many patients living longer than ever before. However, the focus on survival rates and scan results can overshadow the quality of life for those receiving these treatments. A recent study presented at the European Society for Medical Oncology highlights the importance of considering the human experience alongside medical outcomes. Researchers conducted a randomized controlled trial involving 1,137 patients with high-risk melanoma who had undergone surgery. The participants received either pembrolizumab, an established immunotherapy, or a combination of pembrolizumab and an experimental mRNA vaccine designed to target the patient's specific tumor. The study aimed to explore the effects of this personalized approach on the patients' quality of life. While the results showed improved survival rates, the researchers also found that the patients who received the combination therapy experienced more side effects, such as fatigue and skin reactions. This raises questions about the trade-offs between extended life expectancy and the quality of life during treatment. As cancer treatments continue to evolve, it is essential to consider the human experience and the impact of these treatments on patients' daily lives. By doing so, we can work towards creating more holistic and patient-centered care.